Summary:
A multicenter, open-label safety study of dfp-02 (10mg) nasal spray for the treatment of acute migraine in patients with 2 to 6 migraine headaches a month.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Have experienced migraines for the last 12 months or longer
•
Not have aura, or if experiencing aura, it should not be prolonged
•
More inclusion/exclusion criteria apply
Qualified Participants May Receive:
All study-related visits, tests and the investigational nasal spray will be provided to participants at no cost. In addition, reimbursement for study-related time and travel may be provided to participants who qualify. $50 per visit, up to 9 visits total.